---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-26-000083"
form_type: "8-K"
ticker: "CMPX"
cik: "0001738021"
company_name: "Compass Therapeutics, Inc."
filed_at: "2026-01-06T23:59:59+00:00"
generated_at: "2026-05-16T11:32:49.909063+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Compass Therapeutics reports $209M cash, tovecimig PFS/OS data on track Q1 2026; appoints CCO and CMO

## Summary
- Cash and marketable securities estimated at $209M as of Dec 31, 2025; cash runway into 2028.
- Analyses of PFS and OS in tovecimig Phase 2/3 BTC trial expected late Q1 2026; BLA preparation underway.
- CTX-8371: third confirmed response in Hodgkin Lymphoma; expansions open in TNBC and NSCLC.
- Appointed Arjun Prasad as CCO and Cynthia Sirard as CMO effective January 2026.
- CTX-10726 Phase 1 initiation expected Q1 2026 with initial data in H2 2026.

## SEC filing metadata
- accession: 0001171843-26-000083
- form_type: 8-K
- ticker: CMPX
- cik: 0001738021
- company_name: Compass Therapeutics, Inc.
- filed_at: 2026-01-06T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1738021/000117184326000083/0001171843-26-000083-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1738021/000117184326000083/f8k_010626.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-26-000083
- JSON: https://secwatch.observer/filing/0001171843-26-000083.json
- Plain text: https://secwatch.observer/filing/0001171843-26-000083.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.